Share your news! Members can submit news and events in the member portal. Login to start submitting. Local non-profit organizations are invited to apply for Pfizer Connecticut Laboratories 2022/2023 competitive grants.
Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered.
Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school.
Additional grants will be made to programs that provide for the underserved, Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of ageIn participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responsesCompanies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possibleResults in children under 5 years of age are expected as soon as later this year
NEW YORK AND MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA.
This press release features multimedia. View the full release
Local non-profit organizations are invited to apply for Pfizer Connecticut’s 2021/2022 competitive grants.
Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered.
Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school. Additional grants will be made to programs that provide for the underserved or to support local civic Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysisAnalysis evaluated 94 confirmed cases of COVID-19 in trial participantsStudy enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collectedSubmission for Emergency Use Authorization (EUA) to the U.S. Food and Drug In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD) is being evaluated in 45 subjectsAt day 28 (7 days after dose 2), all subjects who received 10 or 30 µg of BNT162b1 had significantly elevated RBD-binding IgG antibodies with geometric mean concentrations (GMCs) of 4,813 and 27,872 units/ml which are 8- and 46.3-times, respectively, the GMC of 602 units/ml in First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine
Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021NEW YORK, USA, and MAINZ, Germany, May 5, 2020 – Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic
Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19. Dr. Albert Bourla, Chairman and CEO, made the following statement: “In this troubling time, Pfizer is committed to doing all we can to respond to the COVID-19 pandemic. Many companies, including Pfizer, are working to develop antiviral Local non-profit organizations are invited to apply for Pfizer Connecticut Laboratories 2020/2021 competitive grants. Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered. Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school. Additional grants will be made to programs that provide for the underserved or to support local Pfizer’s Groton Laboratories and the Clinical Research Unit, New Haven will support more than 60 programs in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island through its 2019 competitive grants program.
Priority was given to programs that bring science and math to students from elementary through high school. Additional awards were made for programs that provide for the underserved or to support local civic and cultural institutions. Groups receiving support in 2019 Groton, CT – Local non-profit organizations are invited to apply for Pfizer Connecticut Laboratories’ 2019/2020 competitive grants. Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered. Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school. Additional grants will be made to programs that provide for the underserved or to Beginning January 1, local non-profit organizations are invited to apply for Pfizer Connecticut Laboratories’ 2019/2020 competitive grants.
Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered. Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school. Additional grants will be made to programs that provide for the Pfizer’s Groton Laboratories and the Clinical Research Unit, New Haven will support more than 60 programs in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island through its 2018 competitive grants program.
Priority was given to programs that bring science and math to students from elementary through high school. Additional awards were made for programs that provide for the underserved or to support local civic and cultural institutions. Groups receiving support in 2018 Local non-profit organizations are invited to apply for Pfizer Groton Laboratories’ 2018/2019 competitive grants. Applications from organizations serving communities in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island will be considered. Priority will be given to programs that bring STEM (science, technology, engineering and math) to students from elementary through high school. Additional grants will be made to programs that provide for the underserved or to support local Pfizer’s Groton Laboratories will support 67 programs in Southeastern Connecticut, the greater New Haven area, and southern Rhode Island through its 2017 competitive grants program.
Priority was given to programs that bring science and math to students from elementary through high school. Additional awards were made for programs that provide for the underserved or to support local civic and cultural institutions.
Groups receiving support in 2017 are:
Aluminum Falcon Robotics Inc. - 2018 FIRST Robotics
Pfizer Awards Grants to 51 of Region's Nonprofits
Pfizer Inc. has announced that 51 nonprofits in Connecticut and Rhode Island, including the Garde Arts Center and Project Oceanology, will receive funding support this year.
Other recipients were Aluminum Falcon Robotics, Bethsaida Community Inc., Center for Hospice Care Southeast Connecticut, Children's Museum of Southeastern Connecticut, Chorus of Westerly, Connecticut College, Eastern Connecticut Ballet, Eastern Connecticut Community Gardens
Pfizer Connecticut Labs Opens Call for 2022 Community Grants
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
Pfizer CT Announces Beginning of 2021 Community Grants Campaign *NEW* Website and Application Process
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-Base Vaccine Candidate Against SARS-CoV-2
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID - 19 mRNA Vaccine
Pfizer Outlines Five-Point Plan to Battle COVID-19
Pfizer Connecticut Labs Opens Call for 2020 Community Grants
Pfizer Awards Community Grants in Connecticut and Rhode Island
Pfizer Connecticut Labs Opens Call for 2019 Community Grants
Pfizer Connecticut Labs Open Call for 2019 Community Grants
Pfizer Announces Community Grants for 2018
Pfizer Groton Labs Opens Call for 2018 Community Grants
Pfizer Awards Community Grants
Pfizer Awards Grants to 51 of Region's Nonprofits
Monday, January 24, 2022
Monday, September 20, 2021
Monday, August 23, 2021
Thursday, January 14, 2021
Monday, November 09, 2020
Wednesday, July 01, 2020
Tuesday, May 05, 2020
Tuesday, March 17, 2020
Thursday, February 13, 2020
Friday, June 07, 2019
Friday, January 04, 2019
Friday, December 07, 2018
Friday, May 18, 2018
Friday, January 05, 2018
Thursday, June 15, 2017
Tuesday, June 02, 2015